Antisense Therapeutics Limited
OTC: ATHJF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- James Garner MBA
- Headquarters
- Toorak, Australia
- IPO year
- 2009
- Market cap
- $19.6M
- Website
- https://www.antisense.com.au
Loading ATHJF…
Loading profile data…Frequently asked questions about ATHJF
What does Antisense Therapeutics Limited (ATHJF) do?
Antisense Therapeutics Limited (ATHJF) is an Australian biotechnology company dedicated to the research and development of innovative antisense pharmaceuticals. Its therapeutic pipeline includes two primary drug candidates. ATL1102, an antisense inhibitor targeting CD49d, is currently in Phase II clinical trials for a variety of inflammatory con...
Where does ATHJF trade?
Antisense Therapeutics Limited (ATHJF) trades on the Other OTC.
What sector is ATHJF in?
Antisense Therapeutics Limited (ATHJF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Antisense Therapeutics Limited?
James Garner MBA is the chief executive officer of Antisense Therapeutics Limited (ATHJF).
Where is Antisense Therapeutics Limited headquartered?
Antisense Therapeutics Limited is headquartered in Australia.
Does ATHJF pay a dividend?
Antisense Therapeutics Limited (ATHJF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ATHJF go public?
Antisense Therapeutics Limited (ATHJF) completed its initial public offering in 2009.